ALDX Key Statistics, Chart & Performance
The current stock price of ALDX is 5.24 USD. In the past month the price increased by 28.57%. In the past year, price decreased by -11.97%.
ALDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALDX. When comparing the yearly performance of all stocks, ALDX is a bad performer in the overall market: 64.62% of all stocks are doing better.
ALDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDX. While ALDX seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALDX Financial Highlights
Over the last trailing twelve months ALDX reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 2.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.52% | ||
| ROE | -87.71% | ||
| Debt/Equity | 0 |
ALDX Forecast & Estimates
12 analysts have analysed ALDX and the average price target is 9.86 USD. This implies a price increase of 88.17% is expected in the next year compared to the current price of 5.24.
ALDX Ownership
ALDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.04 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.76 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.66 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.69 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.06 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALDX
Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Company Info
ALDEYRA THERAPEUTICS INC
131 Hartwell Avenue, Suite 320
Lexington MASSACHUSETTS 02421 US
CEO: Todd C. Brady
Employees: 9
Phone: 17817614904
ALDEYRA THERAPEUTICS INC / ALDX FAQ
What does ALDX do?
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
What is the stock price of ALDEYRA THERAPEUTICS INC today?
The current stock price of ALDX is 5.24 USD. The price increased by 0.38% in the last trading session.
Does ALDX stock pay dividends?
ALDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALDX stock?
ALDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does ALDEYRA THERAPEUTICS INC have?
ALDEYRA THERAPEUTICS INC (ALDX) currently has 9 employees.
Who owns ALDEYRA THERAPEUTICS INC?
You can find the ownership structure of ALDEYRA THERAPEUTICS INC (ALDX) on the Ownership tab.